GSK Plc - ViiV Lai Vs Oral Soc Data In Adherence-Challenged; ViiV Healthcare Announces Interim Data At CROI Indicating Superior Efficacy Of Long-Acting Injectable HIV Treatment Cabenuva; Cabenuva Demonstrated Superior Efficacy In Maintaining Viral Load Suppression Vs Daily Oral Therapy; Latitude Study Rate Of Adverse Events Was Similar In Both Arms
Portfolio Pulse from Benzinga Newsdesk
ViiV Healthcare, a subsidiary of GSK Plc, announced interim data at CROI showing superior efficacy of its long-acting injectable HIV treatment, Cabenuva, compared to daily oral therapy in maintaining viral load suppression. The Latitude study also reported a similar rate of adverse events between both treatment arms.
March 06, 2024 | 4:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK Plc's subsidiary, ViiV Healthcare, announced promising interim data for Cabenuva, its long-acting injectable HIV treatment, showing superior efficacy over daily oral therapy.
The positive interim data from the Latitude study regarding Cabenuva's efficacy and safety profile could lead to increased adoption and sales, positively impacting GSK's financial performance and reputation in the healthcare sector.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90